 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
20 News |  |
- | usmarapride (SUVN-D4010) / Suven Life Sci
Journal: Usmarapride (SUVN-D4010), a 5-HT receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profiling. (Pubmed Central) - Apr 11, 2023
donepezil, rivastigmine, galantamine, memantine etc. either alone or in combination show modest efficacy without changing the course of the disease...Aducanumab, a monoclonal antibody is a disease modifying therapeutic agent targeting the toxic amyloid beta (A?) proteins for its clearance...Usmarapride also potentiated the pharmacological effects of donepezil in animal models. To conclude, usmarapride may be a promising intervention for alleviating the cognitive dysfunction in AD patients with disease modifying potential.
- usmarapride (SUVN-D4010) / Suven Life Sci
Usmarapride Oxalate (SUVN-D4010): A Serotonin-4 Receptor Partial Agonist for the Treatment of Cognitive Disorders () - Jun 24, 2022 - Abstract #AAIC2022AAIC_77;
- | usmarapride (SUVN-D4010) / Suven Life Sci
Journal: A selective and accurate liquid chromatography-tandem mass spectrometry method for the quantitation of the novel 5-HT receptor partial agonist SUVN-D4010 (Usmarapride) in human plasma and urine. (Pubmed Central) - Mar 11, 2022
SUVN-D4010 was found to be stable in human plasma and urine at the defined storage conditions. The validated method was successfully applied to quantitate SUVN-D4010 in human plasma and urine from a clinical first-in-human study conducted to evaluate its safety, tolerability, and pharmacokinetics in healthy adults.
- | usmarapride (SUVN-D4010) / Suven Life Sci
Journal: SUVN-D4010: A serotonin-4 receptor partial agonist for the treatment of cognitive disorders. (Pubmed Central) - Feb 4, 2022
The validated method was successfully applied to quantitate SUVN-D4010 in human plasma and urine from a clinical first-in-human study conducted to evaluate its safety, tolerability, and pharmacokinetics in healthy adults. SUVN-D4010 is a potent, selective, orally bioavailable and brain penetrant 5-HT receptor partial agonist with potential utility in treatment of cognitive disorders.
- usmarapride (SUVN-D4010) / Suven Life Sci
Usmarapride (SUVN-D4010): A 5-HT 4 receptor partial agonist alleviates haloperidol-induced Parkinson’s disease associated cognitive dysfunction (Virtual Only) - Dec 20, 2021 - Abstract #Neuroscience2021Neuroscience_2952;
Significant increase in novel juvenile social investigation time or discriminative index was observed for the groups treated with usmarapride or rivastigmine, relative to familiar juvenile or vehicle control group, respectively. Usmarapride ameliorated PD related dementia in an animal model, thus it could be a future promising therapeutic strategy for PD associated dementia, thereby to improve the patients' hQOL.
- | usmarapride (SUVN-D4010) / Suven Life Sci
Preclinical, Journal: Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's Disease. (Pubmed Central) - Oct 22, 2021
Phase 1 clinical studies have been completed and projected efficacious concentration was achieved without any major safety concerns. Phase 2 enabling long-term safety studies have been completed with no concerns for further development.
- usmarapride (SUVN-D4010) / Suven Life Sci
[VIRTUAL] SUVN-D4010: A serotonin-4 receptor partial agonist for the treatment of cognitive disorders () - Aug 2, 2021 - Abstract #AAIC2021AAIC_2380;
SUVN-D4010 significantly increased extracellular acetylcholine levels as a standalone, or treatment adjunct to donepezil. SUVN-D4010 is a potent, selective, orally bioavailable and brain penetrant 5-HT 4 receptor partial agonist with potential utility in treatment of cognitive disorders.
- || SUVN-D4010 / Suven Life Sci
Clinical, P1 data, PK/PD data, Journal: First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects. (Pubmed Central) - Jun 2, 2021
P1
SUVN-D4010 was well tolerated and safe in elderly subjects after a single dose. Clinical trial identifiers: NCT02575482 and NCT03031574.
- | usmarapride (SUVN-D4010) / Suven Life Sci
Trial completion: A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-D4010 in Healthy Subjects (clinicaltrials.gov) - Sep 25, 2017
P1, N=28, Completed, Sponsor: Suven Life Sciences Limited
Clinical trial identifiers: NCT02575482 and NCT03031574. Recruiting --> Completed
- | usmarapride (SUVN-D4010) / Suven Life Sci
New P1 trial: A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-D4010 in Healthy Subjects (clinicaltrials.gov) - Jan 26, 2017
P1, N=28, Recruiting, Sponsor: Suven Life Sciences Limited
- ||| usmarapride (SUVN-D4010) / Suven Life Sci
Trial completion: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects (clinicaltrials.gov) - Jun 9, 2016
P1, N=64, Completed, Sponsor: Suven Life Sciences Limited
Recruiting --> Completed Recruiting --> Completed
- ||| usmarapride (SUVN-D4010) / Suven Life Sci
New P1 trial: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects (clinicaltrials.gov) - Oct 22, 2015
P1, N=64, Recruiting, Sponsor: Suven Life Sciences Limited